247 related articles for article (PubMed ID: 22735814)
1. Activation of PI3K/Akt signaling by n-terminal SH2 domain mutants of the p85α regulatory subunit of PI3K is enhanced by deletion of its c-terminal SH2 domain.
Hofmann BT; Jücker M
Cell Signal; 2012 Oct; 24(10):1950-4. PubMed ID: 22735814
[TBL] [Abstract][Full Text] [Related]
2. Expression of a mutated form of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO).
Jücker M; Südel K; Horn S; Sickel M; Wegner W; Fiedler W; Feldman RA
Leukemia; 2002 May; 16(5):894-901. PubMed ID: 11986952
[TBL] [Abstract][Full Text] [Related]
3. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
Horn S; Bergholz U; Jücker M; McCubrey JA; Trümper L; Stocking C; Bäsecke J
Oncogene; 2008 Jul; 27(29):4096-106. PubMed ID: 18317450
[TBL] [Abstract][Full Text] [Related]
4. The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors.
Wu CJ; O'Rourke DM; Feng GS; Johnson GR; Wang Q; Greene MI
Oncogene; 2001 Sep; 20(42):6018-25. PubMed ID: 11593409
[TBL] [Abstract][Full Text] [Related]
5. Infectious bursal disease virus activates the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway by interaction of VP5 protein with the p85α subunit of PI3K.
Wei L; Hou L; Zhu S; Wang J; Zhou J; Liu J
Virology; 2011 Aug; 417(1):211-20. PubMed ID: 21723579
[TBL] [Abstract][Full Text] [Related]
6. Domain analysis reveals striking functional differences between the regulatory subunits of phosphatidylinositol 3-kinase (PI3K), p85α and p85β.
Ito Y; Vogt PK; Hart JR
Oncotarget; 2017 Aug; 8(34):55863-55876. PubMed ID: 28915558
[TBL] [Abstract][Full Text] [Related]
7. The SH3 and BH domains of the p85alpha adapter subunit play a critical role in regulating class Ia phosphoinositide 3-kinase function.
Beeton CA; Das P; Waterfield MD; Shepherd PR
Mol Cell Biol Res Commun; 1999 May; 1(2):153-7. PubMed ID: 10356365
[TBL] [Abstract][Full Text] [Related]
8. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.
Sun M; Hillmann P; Hofmann BT; Hart JR; Vogt PK
Proc Natl Acad Sci U S A; 2010 Aug; 107(35):15547-52. PubMed ID: 20713702
[TBL] [Abstract][Full Text] [Related]
9. Cancer-associated mutations in the p85α N-terminal SH2 domain activate a spectrum of receptor tyrosine kinases.
Li X; Lau AYT; Ng ASN; Aldehaiman A; Zhou Y; Ng PKS; Arold ST; Cheung LWT
Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34507989
[TBL] [Abstract][Full Text] [Related]
10. SHP-2 regulates the phosphatidylinositide 3'-kinase/Akt pathway and suppresses caspase 3-mediated apoptosis.
Ivins Zito C; Kontaridis MI; Fornaro M; Feng GS; Bennett AM
J Cell Physiol; 2004 May; 199(2):227-36. PubMed ID: 15040005
[TBL] [Abstract][Full Text] [Related]
11. Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.
Hon WC; Berndt A; Williams RL
Oncogene; 2012 Aug; 31(32):3655-66. PubMed ID: 22120714
[TBL] [Abstract][Full Text] [Related]
12. Functional interactions between isolated SH2 domains and insulin/Ras signaling pathways of Xenopus oocytes: opposite effects of the carboxy- and amino-terminal SH2 domains of p85 PI 3-kinase.
Aroca P; Mahadevan D; Santos E
Oncogene; 1996 Nov; 13(9):1839-46. PubMed ID: 8934529
[TBL] [Abstract][Full Text] [Related]
13. Solution structure of the C-terminal SH2 domain of the p85 alpha regulatory subunit of phosphoinositide 3-kinase.
Siegal G; Davis B; Kristensen SM; Sankar A; Linacre J; Stein RC; Panayotou G; Waterfield MD; Driscoll PC
J Mol Biol; 1998 Feb; 276(2):461-78. PubMed ID: 9512716
[TBL] [Abstract][Full Text] [Related]
14. Defining How Oncogenic and Developmental Mutations of PIK3R1 Alter the Regulation of Class IA Phosphoinositide 3-Kinases.
Dornan GL; Stariha JTB; Rathinaswamy MK; Powell CJ; Boulanger MJ; Burke JE
Structure; 2020 Feb; 28(2):145-156.e5. PubMed ID: 31831213
[TBL] [Abstract][Full Text] [Related]
15. TGF-β promotes PI3K-AKT signaling and prostate cancer cell migration through the TRAF6-mediated ubiquitylation of p85α.
Hamidi A; Song J; Thakur N; Itoh S; Marcusson A; Bergh A; Heldin CH; Landström M
Sci Signal; 2017 Jul; 10(486):. PubMed ID: 28676490
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of PI3K binding to activators by serine phosphorylation of PI3K regulatory subunit p85alpha Src homology-2 domains.
Lee JY; Chiu YH; Asara J; Cantley LC
Proc Natl Acad Sci U S A; 2011 Aug; 108(34):14157-62. PubMed ID: 21825134
[TBL] [Abstract][Full Text] [Related]
17. Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells.
Nieborowska-Skorska M; Slupianek A; Skorski T
Oncogene; 2000 Aug; 19(36):4117-24. PubMed ID: 10962572
[TBL] [Abstract][Full Text] [Related]
18. Activation of the focal adhesion kinase signaling pathway by structural alterations in the carboxyl-terminal region of c-Crk II.
Zvara A; Fajardo JE; Escalante M; Cotton G; Muir T; Kirsch KH; Birge RB
Oncogene; 2001 Feb; 20(8):951-61. PubMed ID: 11314030
[TBL] [Abstract][Full Text] [Related]
19. Multiple roles for the p85α isoform in the regulation and function of PI3K signalling and receptor trafficking.
Mellor P; Furber LA; Nyarko JN; Anderson DH
Biochem J; 2012 Jan; 441(1):23-37. PubMed ID: 22168437
[TBL] [Abstract][Full Text] [Related]
20. Thyroid-hormone-dependent activation of the phosphoinositide 3-kinase/Akt cascade requires Src and enhances neuronal survival.
Cao X; Kambe F; Yamauchi M; Seo H
Biochem J; 2009 Nov; 424(2):201-9. PubMed ID: 19747164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
